Change in PDL Status for the Immunomodulators, Atopic Dermatitis and Ophthalmics, Anti-Inflammatories Drug Classes

Date: April 7, 2025

Attention: Providers

Effective date: April 4, 2025

Call to action: Effective April 4, 2024, the Texas Health and Human Services (HHS) removed non-preferred status from generic pimecrolimus cream and loteprednol eye drop suspension. This is in response to a drug shortage of the preferred brand name product Elidel 1% cream (pimecrolimus) and drug discontinuation of the preferred name product Lotemax 0.5% Eye Drop suspension (loteprednol etabonate 0.5%).

How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.

Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.

If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org. 

For access to all provider alerts,log into:
www.texaschildrenshealthplan.org/provideralerts